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ABSTRACT
Background The Veterans Health Administration 
COVID- 19 (VACO) Index predicts 30- day all- cause 
mortality in patients with COVID- 19 using age, sex and 
pre- existing comorbidity diagnoses. The VACO Index 
was initially developed and validated in a nationwide 
cohort of US veterans—we now assess its accuracy in an 
academic medical centre and a nationwide US Medicare 
cohort.
Methods With measures and weights previously 
derived and validated in US national Veterans Health 
Administration (VA) inpatients and outpatients 
(n=13 323), we evaluated the accuracy of the VACO 
Index for estimating 30- day all- cause mortality using 
area under the receiver operating characteristic curve 
(AUC) and calibration plots of predicted versus observed 
mortality in inpatients at a single US academic medical 
centre (n=1307) and in Medicare inpatients and 
outpatients aged 65+ (n=427 224).
Results 30- day mortality varied by data source: VA 
8.5%, academic medical centre 17.5%, Medicare 
16.0%. The VACO Index demonstrated similar 
discrimination in VA (AUC=0.82) and academic medical 
centre inpatient population (AUC=0.80), and when 
restricted to patients aged 65+ in VA (AUC=0.69) and 
Medicare inpatient and outpatient data (AUC=0.67). The 
Index modestly overestimated risk in VA and Medicare 
data and underestimated risk in Yale New Haven 
Hospital data.
Conclusions The VACO Index estimates risk of short- 
term mortality across a wide variety of patients with 
COVID- 19 using data available prior to or at the time 
of diagnosis. The VACO Index could help inform primary 
and booster vaccination prioritisation, and indicate who 
among outpatients testing positive for SARS- CoV- 2 
should receive greater clinical attention or scarce 
treatments.
INTRODUCTION
Current age and pre- existing medical condition 
criteria for COVID- 19 vaccine prioritisation1 2 
identify a significant proportion of the world adult 
population, exceeding available vaccine supplies. A 
more tailored risk estimation combining age with 
pre- existing conditions could provide a more gran-
ular approach to prioritisation,3 and play a role 
in: (1) motivating high- risk individuals and their 
contacts to practise social distancing until vacci-
nated, (2) identifying individuals testing positive 
at drive- up sites who require clinical examination 
and possibly laboratory evaluation, and (3) priori-
tising patients for primary or booster vaccination or 
scarce treatments.
Hundreds of publications have identified 
risk factors associated with adverse COVID- 19 
outcomes,4 5 but just a small subset have developed 
predictive models using electronic health record 
(EHR) or administrative data available prior to infec-
tion and that are readily analysable, enabling rapid 
and large- scale identification of those at greatest 
risk should they become infected.6–10 Even fewer 
studies have prospectively validated their models 
in large samples. The Veterans Health Administra-
tion COVID- 19 (VACO) Index for short- term, all- 
cause mortality is based on age, sex and comorbid 
diagnoses, and was developed and validated using 
EHR data from a nationwide cohort from the US 
Veterans Health Administration (VA).11 Within VA, 
the VACO Index demonstrated good discrimination 
across time intervals and among men and women, 
White, Black and Hispanic patients and those living 
in different geographic regions. The Index is avail-
able as a web application at  MDCalc. com and as a 
mobile application for iOS and Android platforms. 
An EHR decision support tool which autopopulates 
Index data elements is currently in development.
Some have questioned the generalisability of 
VA data for understanding risk of mortality from 
COVID- 19. US veterans in care are predominantly 
male, older and have a higher prevalence of chronic 
health conditions and risk behaviours than the US 
population.12–14 To address these concerns, we 
compare the accuracy (discrimination and calibra-
tion) of VACO Index short- term mortality estimates 
for patients with COVID- 19 in: (1) our original 
US nationwide VA sample of 13 323 inpatients 
and outpatients, (2) 1307 patients admitted to 
Yale New Haven Hospital (YNHH, a tertiary care 
academic medical centre drawing from Southern 
New England, New York state and beyond), and 
(3) 441 854 US nationwide Medicare recipients 
(aged 65 and older). We consider the accuracy of 
the Index overall and within important subgroups 
defined by calendar time, age, sex, race/ethnicity 
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and geographic region. We also consider whether different 
weighting of the index components or adding race/ethnicity 




The VACO Index, a 30- day all- cause mortality prediction 
model developed and validated in VA nationwide data, uses 
demographic and pre- existing condition data available in EHR 
or medical administrative data.11 The Index includes age, sex, 
multimorbidity quantified with the Charlson Comorbidity Index 
(CCI) derived from International Classification of Diseases, 
10th Edition (ICD- 10) diagnosis codes (online supplemental 
file 1)15 16 and myocardial infarction (MI) or peripheral vascular 
disease (PVD)—neither race nor any other individual comorbid 
diagnosis provided additional discriminatory function (online 
supplemental file 2). The VACO Index had an area under the 
receiver operating characteristic curve (AUC) of 0.79 in devel-
opment, 0.81 in early validation and 0.84 in later validation, 
and validated well in sex, race/ethnicity and regional subgroups.
Data source and participants
VA data
We used a nationwide sample of 13 323 veterans testing positive 
for SARS- CoV- 2 in the inpatient or outpatient setting between 
2 March 2020 and 15 April 2020 and followed for 30 days. 
VA data were split into development (test positive 2 March 
2020 to 15 April 2020), early validation (16 April 2020 to 
18 May 2020) and later validation (19 May 2020 to 19 July 
2020) cohorts. Deaths were determined using inpatient records 
and the VA death registry to capture deaths occurring outside 
hospitalisation.
YNHH data
We extracted data from the YNHH Epic (Epic Systems, Madison, 
Wisconsin, USA) EHR on 1307 patients testing positive for 
SARS- CoV- 2 between 2 March 2020 and 19 July 2020 who 
were admitted to the hospital. Patients were eligible for inclu-
sion if they tested positive within 14 days before an admission, 
on the day of admission or while hospitalised. Similar to the 
VACO Index methodology, we used the first SARS- CoV- 2 posi-
tive test date, and baseline was the date of positive testing for 
those admitted within 14 days after testing positive, or date of 
testing for those testing positive more than 14 days after admis-
sion (presumably a nosocomial infection).
Thirty- day deaths were determined by index hospitalisa-
tion discharge status and postdischarge deaths captured by the 
healthcare system EHR. YNHH data were restricted to inpatient 
deaths during the YNHH index and subsequent admissions, and 
any outpatient deaths recorded in the YNHH EHR, so we did 
not have complete 30- day mortality capture as in the VA data.
Medicare data
We used US Medicare Fee for Service data to identify 427 224 
patients nationwide aged 65 or older with an inpatient or outpa-
tient COVID- 19 diagnosis between 2 March 2020 and 19 July 
2020, using ICD- 10 diagnosis code of B97.29 on pre- April 
data and U07.1 stating 1 April 2020. Deaths were ascertained 
by discharge status after any Medicare hospitalisation, supple-
mented with deaths recorded in the Medicare database.
Data harmonisation
For all data sets, we categorised data into identical age, race, and 
sex strata and determined CCI scores from ICD- 10 diagnosis 
codes. If an individual had a COVID- 19 diagnosis code on more 
than one date, we only included the first date. Data were split 
into ‘early’ and ‘later’ cohorts temporally synchronised with 
the VACO Index development cohort and combined validation 
early and late cohorts. We used an identical 30- day follow- up 
window for determining death. We explored the more gran-
ular race stratification available in Medicare data (non- Hispanic 
White, non- Hispanic Black, Hispanic, Asian, North American 
Native, Other). In VA and Medicare data sets we also considered 
the most recent BMI recorded between 730 and 15 days before 
baseline.
Statistical analyses
We used multivariable logistic regressions to model 30- day all- 
cause mortality. To account for missing BMI data in the VA and 
YNHH data sets, we used multiple imputation by chained equa-
tions, including all predictor and outcome variables and auxiliary 
variables, generated 10 imputed data sets for the development 
and validation cohorts, and proportions, ORs and 95% CIs were 
combined according to Rubin’s rules.17
We report the AUC and calibration plots as assessments of the 
VACO Index performance and of alternative models in all three 
data sets. We used the VACO Index coefficients to calculate a 
predicted mortality for each patient in the YNHH and Medi-
care data sets, and then determined AUCs for the early and later 
testing dates, and in important subgroups: age (<65 vs 65+, 
except in Medicare data), sex (male vs female), race/ethnicity 
(Black vs non- Black), US census region (except in YNHH 
data), and compared the values to those obtained in the orig-
inal VACO Index development cohort. We refit models using 
the VACO Index variables in the VA, YNHH and Medicare data 
sets to understand how the model might have differed had it 
been developed in alternative data sets. To assess the impact of 
race and BMI, we also refit models supplementing VACO Index 
variables with race (VA, YNHH and Medicare) and BMI (VA, 
YNHH).
We assessed calibration plots of observed versus predicted 
30- day mortality in 10 (VA and Medicare data) or five (small 
sample size: YNHH data, VA female subgroup) strata containing 
equal numbers of deaths in early and later testing cohorts and in 
subgroups by age, sex, race/ethnicity and US census region. Data 
analyses were performed using Stata V.15.1 (StataCorp, College 
Station, Texas, USA) and SAS V.9.4 (SAS Institute). This study 
was conducted in compliance with the Health Insurance Porta-
bility and Accountability Act. Neither the patients nor the public 
were involved in the design, conduct, reporting or dissemination 
of this research. Dissemination of results to deidentified subjects 
is not practicable. This cohort study is reported according to 
the Transparent Reporting of a Multivariable Prediction Model 




The data set included 13 323 VA, 1307 YNHH and 427 224 
Medicare patients for a total of 441 854 patients with COVID- 19 
(online supplemental file 4). Compared with VA (median age 63 
years) and YNHH (65 years), Medicare patients (78 years) were 
older; a higher proportion of Medicare patients were White 
(75%) compared with YNHH (44%) and VA (39%); YNHH had 
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the largest proportion of Hispanic patients (21%). Women were 
better represented in YNHH (52%) and Medicare (58%) than in 
VA (9%). Consistent with the older age of the Medicare cohort, 
most comorbid conditions were substantially more common.
Performance in the YNHH cohort
The VACO Index demonstrated good discrimination in YNHH 
data overall (AUC: 0.80, 95% CI 0.77 to 0.83), consistent with 
that seen in VA overall (AUC: 0.82, 95% CI 0.81 to 0.83) (table 1). 
Discrimination in YNHH early and later periods was similar to 
the VA development period. When AUCs were estimated for 
subgroups, the VACO Index demonstrated similar discrimina-
tion in YNHH data as in VA data among those <65 years of age, 
those 65 and over, men, non- Hispanic Black patients, Hispanic 
patients and Other race/ethnicity patients. The discrimination 
among non- Hispanic White patients at YNHH was not as strong 
(AUC: 0.72, 95% CI 0.67 to 0.77) as in VA (AUC: 0.82, 95% 
CI 0.81 to 0.84), while good discrimination among women in 
YNHH (AUC: 0.81, 95% CI 0.77 to 0.85) was not as strong as 
among women in VA (AUC: 0.88, 95% CI 0.81 to 0.95).
Performance in the Medicare cohort
Restricting VA data to the age range included in Medicare (65 
years or older), the VACO Index demonstrated consistent AUCs 
in VA and Medicare data (table 2). In all cases, the AUCs esti-
mated within Medicare data fell within the 95% CI for the VA 
AUCs overall and by testing date, sex, race/ethnicity and census 
region.
The VACO Index modestly overestimated mortality in VA 
data and Medicare population, underestimated risk in the 
YNHH population (figure 1) and performed well in subgroups 
(online supplemental file 5). Of note, the Index slightly underes-
timated risk in the early interval of Medicare data but was better 
calibrated among Black, Hispanic, Asian and North American 
Native than among White patients.
Table 1 Validation of VACO Index 30- day COVID- 19 mortality estimates in subgroups of VA, YNHH and Medicare cohorts
All adults Age 65+
VA YNHH VA Medicare
n 13 323 1307 6035 427 224













































































  Asian * * * 0.66
(0.64 to 0.67)
  North American Native * * * 0.63
(0.61 to 0.66)

































*Asian and North American Native subgroups had small sample sizes, and thus were collapsed into the Other subgroup.
†Virtually all YNHH patients were from the Northeast census region.
AUC, area under the receiver operating characteristic curve; VA, Veterans Health Administration; VACO, Veterans Health Administration COVID- 19; YNHH, Yale New Haven Hospital.
copyright.
 on O

















4 King, Jr. JT, et al. J Epidemiol Community Health 2021;0:1–7. doi:10.1136/jech-2021-216697
Original research
VACO Index supplemented with race and BMI
Compared with the original VACO Index (table 2, model 1), 
the addition of race and BMI did not improve AUCs in VA, 
YNHH or Medicare data (models 2 and 3). Refitting the VACO 
Index variables in YNHH and Medicare data improved the AUC 
by a single point (model 4), but adding race and BMI to the 
refit did not further improve the AUCs (models 5 and 6). Fully 
adjusted models AUCs (models 7–12) fell largely within the CIs 
estimated in the earlier models. Forest plots of ORs from the 
VACO Index and refitted models in VA, YNHH and Medicare 
data using VACO Index variables supplemented with race and 
BMI showed similar ORs for age, sex, race, CCI, MI or PVD, 
and BMI (figure 2).
DISCUSSION
Based on age, sex and pre- existing conditions, the VACO Index 
maintains good discrimination and calibration for short- term 
mortality among patients with COVID- 19 in two demographi-
cally diverse samples outside the VA healthcare system. Adjusted 
associations identified in VA data are largely consistent in YNHH 
and Medicare data, demonstrating that relative weights assigned 


























































































































*YNHH early and late cohorts combined due to small sample size.
†BMI not in Medicare data set, thus no Medicare multivariable models containing BMI possible.
AUC, area under the receiver operating characteristic curve; BMI, body mass index; CCI, Charlson Comorbidity Index; VA, Veterans Health Administration; VACO, Veterans Health Administration 
COVID- 19; YNHH, Yale New Haven Hospital.
Figure 1 Calibration plots comparing Veterans Health Administration COVID- 19 (VACO) Index predicted and observed 30- day mortality in (A) 
Veterans Health Administration (VA) data, (B) Yale New Haven Health (YNHH), and (C) Medicare data. The dashed diagonal line represents perfect 
prediction. Values above the dashed line indicate overprediction of mortality by the VACO Index, and values below the line represent underprediction. 
Error bars depict 95% CIs of mortality predictions.
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variables in the VACO Index are reasonably consistent with the 
weights that would be assigned with YNHH or Medicare data. 
These findings suggest that COVID- 19 mortality risk factors 
seen in VA data generalise to other US populations. Additionally, 
even though mortality rates have decreased over time, the index 
effectively discriminates those at greater risk of mortality in both 
time periods within all three samples. This is true regardless of 
patient sex, race/ethnicity or region of the country.
The VACO Index demonstrates that while age is a major driver 
of COVID- 19 mortality, comorbid disease burden quantified by 
CCI further stratifies risk. When we separately modelled all 17 
conditions in the CCI individually, the AUCs were improved by 
0.01. However, the weighting assigned to the individual condi-
tions varied more across cohorts than did the weighting assigned 
the CCI score (data not otherwise shown)—thus a model fit to 
individual conditions would be less likely to generalise as well 
to new data. Furthermore, we found additional predictive value 
in including MI and PVD as individual variables, in addition to 
their contribution to the CCI score.
Given the ready accessibility of the VACO Index on  MDCalc. 
com, we anticipate several immediate applications. An important 
issue is management of those undergoing testing in drive- up 
settings. A follow- up phone call to notify an individual that they 
are positive currently includes a few questions about fever and 
shortness of breath. If neither are present the patient is advised to 
quarantine. However, some of these individuals may be at high 
risk for serious illness or mortality, justifying a more complete 
clinical evaluation incorporating vital signs, laboratory tests and/
or imaging. As primary and booster vaccines and therapeutic 
options may be in limited supply, the VACO Index could help 
health systems and governments develop a data- driven approach 
to allocating resources to those at greatest risk of mortality who 
are most likely to benefit.
Minority populations experienced a greater burden of infec-
tion in the beginning of the pandemic,19 leading to suggestions 
that overall population risk may seem a more equitable criterion 
for vaccine prioritisation. However, modelling population risk 
of mortality from COVID- 19 encompasses two distinct compo-
nents: probability of infection (infection detection dependent on 
access to testing and probability of a positive test) and prob-
ability of dying once infected. The associations between risk 
factors such as age, race and ethnicity are very different for being 
tested, testing positive and mortality.19 The geographic distribu-
tion of the pandemic has shifted rapidly over time, rendering 
testing positive a volatile outcome that has fluctuated with local 
disease prevalence. Thus, we argue that the best strategy is to 
prioritise those at greatest risk of mortality if infected.
Given the debate over the roles of BMI and race/ethnicity in 
COVID- 19 outcomes, we carefully investigated their associa-
tions with mortality in our data. Including BMI in the Index 
did not improve the discrimination of the Index in VA or 
YNHH data. US and European studies have shown conflicting 
results about the relationship between BMI and COVID- 19 
mortality.20–24 Adding race/ethnicity to the VACO Index did 
not improve the accuracy of the predictions. Further, associa-
tions with race/ethnicity varied among the cohorts, with Black 
race and Hispanic ethnicity associated with reduced risk of 
mortality in VA and YNHH data and increased risk among 
Medicare patients. Since race and ethnicity are largely proxies 
for socioeconomic disparities,25 it is not surprising that their 
association with mortality among those testing positive for 
SARS- CoV- 2 is variable. National VA data frequently demon-
strate fewer disparities by race in health outcomes than outside 
VA, likely from reduced economic barriers to care and national 
efforts to ensure quality of care.26 27 While we considered 
offering an adjustment for race/ethnicity to be applied outside 
VA, we are concerned that adding race/ethnicity would intro-
duce substantial noise in the risk estimation due to variation 
in association across facilities and would confuse biology and 
socioeconomics.25 28 Importantly, the VACO Index demon-
strated consistent or better accuracy in racial and ethnic 
minority patients than in Non- Hispanic White patients.
The VACO Index modestly overestimated mortality in VA 
and Medicare populations and underestimated in the YNHH 
population. The Index was developed using patients diag-
nosed early in the pandemic, and improvements in care over 
time have decreased COVID- 19 mortality.29 YNHH data had 
incomplete capture of comorbidities for some patients with 
limited healthcare system contact prior to infection, resulting 
Figure 2 Forest plot of multivariable models of COVID- 19 30- day 
mortality. Veterans Health Administration COVID- 19 (VACO) Index 
original model includes age, sex, Charlson Comorbidity Index and age 
interaction term, and myocardial infarction (MI) or peripheral vascular 
disease (PVD). Veterans Health Administration (VA) data model refits 
VACO Index variables and adds body mass index (BMI) and race 
(non- Hispanic White, non- Hispanic Black, Hispanic, Other). Yale New 
Haven Health (YNHH) data model refits VACO Index variables and 
adds BMI and race (non- Hispanic White, non- Hispanic Black, Hispanic, 
Other). Medicare data model refits VACO Index variables and adds 
additional race categories (non- Hispanic White, non- Hispanic Black, 
Hispanic, Asian North American Native, Other). Models and ORs of most 
variables are consistent across the data sets, providing evidence of the 
generalisability of the VACO Index model.
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in a modest underestimation of mortality. Nevertheless, the 
calibration plots show a monotonic increase in mortality with 
higher VACO Index scores, identifying patients at greatest risk 
of death should they become infected, and thus who should be 
prioritised for primary and booster vaccinations and greater 
clinical attention or scarce treatments.
The discrimination of the VACO Index quantified by AUC 
in Medicare patients was lower than in VA or YNHH patients 
overall. This discrepancy is related to the reciprocal relation-
ship between the proportion of outcome events in a population 
and AUC—all else equal, the AUC will be lower in populations 
where the outcome is more common, or when a major driver 
of risk (ie, age) has a reduced range.30 31 Importantly, the AUC 
was highly consistent in patients 65 years and over across VA 
and Medicare patients, and calibration curves in Medicare 
data demonstrated good agreement between observed and 
expected mortality rates across race/ethnicity.
Our goal was to develop and validate a short- term COVID- 19 
mortality index using preinfection data—demographics 
and comorbidities—to inform patient, provider, health-
care organisations and government decision- making about 
social distancing, masking, additional testing, primary and 
booster vaccinations and allocation of scarce resources. Most 
published validated COVID- 19 mortality risk indices use clin-
ical information collected at the time of diagnosis—symptoms, 
vital signs, laboratory findings, imaging—that may be already 
influenced by the infection, and thus are not comparable to 
the VACO Index.8 32–37 Others appear to have similar or supe-
rior performance to the VACO Index, but have a more limited 
denominator (eg, only inpatients38), a different outcome (eg, 
mortality data limited to inpatient stay,6 a combined outcome 
of infection and mortality7) or were not validated in a nation-
wide data set.6 9 10 39
There are limitations to our study. While we were able to 
evaluate the index in a US national sample of over 440 000 
people, most of our patients were over 50 years old, limiting 
our ability to validate in younger patients. Our calibration is 
based on mortality events occurring before August 2020 when 
mostly symptomatic patients were being tested. The VACO 
Index may overestimate risk of mortality among asymptomatic 
patients, and this will require further study. Nevertheless, the 
VACO Index represents the most widely validated risk index 
for short- term mortality from COVID- 19. This standardised 
and validated index can supplement clinical judgement to help 
inform patient management and health policy.
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What is already known on this subject
 ► Many COIVD- 19 mortality indices use complex clinical, 
laboratory or imaging data that are often not readily 
available or analysable, concatenate COVID- 19 infectivity 
and mortality, have poor discrimination or are derived from a 
regional population.
 ► A generalisable COVID- 19 mortality risk index based on 
demographics and pre- existing conditions could inform 
patients and providers considering COVID- 19 mitigation, 
prevention and treatment options even before patients 
present to a healthcare system.
 ► The Veterans Health Administration COVID- 19 (VACO) 
Index, developed and validated in a nationwide US veteran 
population, predicts COVID- 19 30- day mortality based on 
data directly accessible in the electronic health record: age, 
sex and pre- existing medical conditions.
What this study adds
 ► We assessed the generalisability of the VACO Index by 
assessing its accuracy in a US academic medical centre 
inpatient population and a nationwide US Medicare inpatient 
and outpatient cohort (aged 65 and older).
 ► The VACO Index modestly overestimates risk in Veterans 
Health Administration and Medicare patients and 
underestimates risk in an academic medical centre 
population. The Index has consistent performance over time, 
and among important patient subgroups including women, 
Blacks, Hispanics, Asians and Native Americans. The VACO 
Index is generalisable and could inform primary and booster 
vaccination prioritisation, and among outpatients who test 
positive for SARS- CoV- 2, indicate who should receive greater 
clinical attention or scarce treatments.
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